Events

Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has announced the appointment of Jason Carroll as its non-executive chairman.

AusBiotech, the national voice of Australia’s life sciences industry, is seeking a head of investment to lead the next chapter in its sector leadership.

Amplia Therapeutics (ASX:ATX) has announced that an additional confirmed partial response has been recorded in its ongoing ACCENT clinical trial in pancreatic cancer.

Prescient Therapeutics (ASX:PTX) has opened its share purchase plan to raise $7 million to advance PTX-100 through Phase 2 clinical development toward potential regulatory approval.

AusBiotech is now inviting member submissions for the upcoming October 2025 edition of the Australasian Biotechnology journal — the sector’s long-standing platform for sharing insights, innovation, and expertise across the life sciences ecosystem.

Clinical stage biotechnology company Neurizon Therapeutics (ASX:NUZ) has executed an exclusive global license agreement with Elanco Animal Health.

PYC Therapeutics (ASX:PYC) has presented data supporting the progress made in its PYC002 program at the Phelan-McDermid Syndrome Global Congress to be held in Spain.

Percheron Therapeutics (ASX:PER) has entered into a worldwide exclusive license agreement with Hummingbird Bioscience, a venture-backed biotechnology company based in Singapore, for HMBD-002, a monoclonal antibody therapy with potential applications in various cancer indications.

QBiotics chair, Mark Fladrich, said, “On behalf of my fellow directors, we are delighted to welcome Sergio to the Board of QBiotics."

Arovella Therapeutics (ASX:ALA) has announced that Dr Thomas Duthy is retiring effective 1 July as a non-executive director and chairman of the company to pursue new business opportunities.

Tetratherix (ASX:TTX) has officially listed on the Australian Securities Exchange after raising $25 million in its initial public offering.

LTR Pharma (ASX:LTP) has announced that it has achieved its latest regulatory milestone for SPONTAN with the successful completion of extractables testing and the launch of its leachables studies.